Table 11.
Adverse events reported during the 12 months of follow-up.
| Ivermectin x 3 | Ivermectin x 2 | Ivermectin x 1 | 0verall | |
|---|---|---|---|---|
| Number of participants | 100 | 52 | 45 | 197 |
| Ae reported | 84 | 44 | 41 | 169 |
| Average number of AE per person | 0.84 | 0.85 | 0.91 | 0.86 |
| AE possibly related to the treatment, n (%) | 64 (76) | 37 (84) | 32 (78) | 133 (79) |
| AE severity | ||||
| Minimal, n (%) | 31 (37) | 14 (32) | 11 (27) | 56 (33) |
| Moderate, n (%) | 34 (41) | 21 (48) | 20 (49) | 75 (44) |
| Severe, n (%) | 17 (20) | 6 (14) | 10 (24) | 33 (20) |
| Life-threatening, n (%) | 1 (1) | 2 (5) | 0 | 3 (2) |
| Fatal outcome, n (%) | 5 (6) | 3 (7) | 4 (10) | 12 (7) |
| Any SAE, n (%) | 13 (16) | 3 (7) | 4 (10) | 20 (12) |
| SAE possibly related to the treatment, n (%) | 9 (11) | 1 (2) | 2 (5) | 12 (7) |
AE: adverse event; SAE: serious adverse events.